Drug Profile


Alternative Names: MRE-0094

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator New York University
  • Developer King Pharmaceuticals Research and Development
  • Class Anti-inflammatories; Purine nucleosides; Small molecules
  • Mechanism of Action Adenosine A2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetic foot ulcer

Most Recent Events

  • 26 Feb 2008 Sonedenoson is still in Phase II trials for wound healing in the United States
  • 08 Sep 2005 Phase-II clinical trials in Diabetic foot ulcer in USA (Topical)
  • 15 Jan 2004 King Pharmaceuticals has completed initial dosing in an ongoing phase I trial of topical MRE 0094 for diabetic neuropathic foot ulcers.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top